Overview

A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression

Status:
Unknown status

Trial end date:
2013-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to see whether combination of low dose lenalidomide(10mg)+ dexamethasone is equally effective in treating relapsed/refractory myeloma in the group of elderly patients and other patients at risk of myelosuppression, whilst producing less side effects, especially myelosuppression compared to the higher dose of lenalidomide of 25mg used in the MM-009 and MM-010 trials.

Phase:

Phase 2

Details

Lead Sponsor:

Peter MacCallum Cancer Centre, Australia

Collaborator:

Celgene Corporation

Treatments:

Aspirin
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Lenalidomide
Thalidomide